Current Edition

Aduhelm

Biogen piles on more long-term Aduhelm data, linking biomarker to Alzheimer’s clinical benefit

Despite a disastrous commercial rollout, Biogen is still producing longer-term data for beleaguered Alzheimer’s disease therapy Aduhelm. In patients who’ve been treated with Aduhelm for …

Continue Reading →
Aduhelm

Biogen’s Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst

During a January Q&A call with investors, Biogen chief Michel Vounatsos pressed Aduhelm supporters to fight the Centers for Medicare & Medicaid Services’ (CMS’) restrictive …

Continue Reading →
Aduhelm

Biogen’s Aduhelm records one patient death. Is the controversial Alzheimer’s drug to blame?

Doctors already have reservations about Biogen’s controversial Alzheimer’s disease drug, Aduhelm. Now a reported death will likely trigger more doubts around its use. One patient …

Continue Reading →
Aduhelm

Citing ‘less-than-optimal’ outcomes for Roche’s Evrysdi, Biogen launches high-dose Spinraza trial

While much of the attention on Biogen lately has centred on its launch of controversial Alzheimer’s disease drug Aduhelm, the company is also feeling the …

Continue Reading →